Data / Form D filings / Outpace Bio, Inc.
Outpace Bio, Inc.: Form D filing
Outpace Bio, Inc., a biotechnology company in Seattle, WA, filed a Form D with the SEC in 2024. The latest, on August 1, 2024, reports $56 million sold of a $144.2 million offering to 25 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 700 Dexter Ave N, Suite 300, Seattle, WA, 98109
- Phone
- (206) 422-1367
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2031531
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 1, 2024 | New notice | $144,235,245 | $55,999,992 | $88,235,253 | 25 | Jul 17, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jake Simson | Director | |
| Aaron Foster | Executive Officer | |
| Bahija Jallal | Director | |
| Vasudev Bailey | Director | |
| Charity Scripture | Executive Officer | |
| Scott Boyken | Executive Officer, Director, Promoter | |
| Eric Soller | Executive Officer | |
| Marc Lajoie | Executive Officer, Director, Promoter |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Jul 29, 2024 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Outpace Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.